Back to the list
Congress: ECR25
Poster Number: C-10194
Type: Poster: EPOS Radiographer (scientific)
Authorblock: A. Masperi, C. M. Girlando; Abbiategrasso/IT
Disclosures:
Andrea Masperi: Nothing to disclose
Cristiano Michele Girlando: Nothing to disclose
Keywords: Oncology, Radiographers, CT, MR, PET-CT, Experimental investigations, Technology assessment, Cancer, Metastases, Quality assurance, Sustainability
Purpose Although the most common site of Metastatic Breast Cancer (MBC) is bone there is currently no standardized imaging modality that offers accurate assessment of bone treatment response.Computed Tomography (CT) is a standard method for evaluating metastatic breast cancer (MBC) but has limitations in assessing bony metastases. RECIST 1.1 criteria classify bone lesions as non-measurable unless there is measurable soft tissue involvement. CT struggles with qualitative assessment, especially for stable lesion sizes or sclerotic responses. Bone Scan (BS) using 99mTc-MDP has...
Read more Methods and materials Population: This retrospective study analyzed 78 patients (median age: 57 years, range: 32-81 years) who participated in a diagnostic protocol between September 2019 and July 2023. All patients underwent WB-MRI (Diagnostic Line 1, DL1) and one of the two reference diagnostic pathways: FDG-PET/CT (Diagnostic Line 2, DL2) or BS with CT-CAP (Diagnostic Line 3, DL3).Study Design: The study evaluated four imaging modalities: WB-MRI, FDG-PET/CT, BS and CT-CAP,. The study was divided into three phases: Study of the standard protocols of the proposed...
Read more Results Population: A total of 70 patients (89.7%) were analyzed, while 8 were excluded as their imaging was performed using different equipment and protocols. All patients participated in DL1, while DL2 (FDG PET/CT staging) involved 29/70 (41.4%) patients, and DL3 (staging with BS and CT-CAP) involved 41/70 (58.6%). As data on consumption and administration of contrast medium and radiopharmaceuticals were not available, it was decided to exclude these patients from the analysis.Scan Time: The overall scan time varied significantly between diagnostic lines....
Read more Conclusion The new horizons of advanced imaging, especially in oncology, will increasingly have to consider not only the aspect of diagnostic efficacy but also that of energy and biological sustainability for patients. This study represents a first approach in the evaluation of energetically and biologically sustainable diagnostic lines for patients with MBC, in particular, important results were highlighted as described below: Reduction of electricity consumption and CO2 emissions by -55% per patient with DL2 vs DL1 and a reduction of electricity consumption...
Read more References [1]         D. Front, S. O. Schneck, A. Frankel, and E. Robinson, “Bone Metastases and Bone Pain in Breast Cancer: Are They Closely Associated?,” JAMA: The Journal of the American Medical Association, vol. 242, no. 16, pp. 1747–1748, 1979, doi: 10.1001/jama.1979.03300160027019.[2]         C. Suzuki et al., “Radiologic measurements of tumor response to treatment: practical approaches and limitations.,” Radiographics, vol. 28, no. 2, pp. 329–344, 2008, doi: 10.1148/rg.282075068.[3]         L. H. Schwartz et al., “RECIST 1.1 - Update and clarification: From the RECIST committee,”...
Read more
GALLERY